The Phase 1 trial will take place at the Nestlé Research Center in Lausanne, Switzerland. Over 60 healthy men and women of 60 years of age or older will be taking part in the study; participants will be reimbursed for their expenses and time.
Information about the trial is presented in a patient-friendly manner on the TrialReach website (http://www.trialreach.com/
TrialReach’s website combines a specialised search engine, exclusive patient-friendly information and fast communication channels between patients and physicians to make clinical trials easy to find, easy to understand, and easy to access.
“Nestlé is the fourth major corporation so far this year to endorse our platform by selecting TrialReach to support their patient recruitment for clinical trials”, said Pablo Graiver, Co-founder and CEO of TrialReach. “We’re delighted that such a prestigious research centre has selected TrialReach and look forward to partnering with other corporations as we roll out our product”.
About Nestlé Research
The Nestlé Research Center is at the heart of fundamental scientific research and innovation within Nestlé. Our role is to drive science and technology, from basic nutrition and health research, to applied research for product development and application. The NRC supports all of Nestlé’s product categories with scientific and technological expertise. For more information, please visit http://www.research.nestle.com
Founded in 2009 and headquartered in London, United Kingdom, TrialReach is a search and referral engine for clinical trials, dedicated to making clinical trials easy to find, easy to understand, and easy to access. A poster-child of Health 2.0, TrialReach leverages the latest technologies and marketing tools to bridge the gap between patients wanting to take part in clinical trials and sponsors and investigators seeking to recruit participants. TrialReach received funding to develop its platform from European VC, Amadeus Capital Partners. For more information about the company, visit http://www.trialreach.com
Media Contact :
+44 208 439 9431